Press Release

Transcend Therapeutics announces publication of new preclinical data demonstrating TSND-201 (methylone) is a rapid-acting neuroplastogen with fewer off-target effects than MDMA

Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1

Transcend and Yale awarded U.S. Department of Defense grant to study methylone for PTSD

Transcend Therapeutics announces Series A funding round of $40 million